Top life sciences deals worldwide by value 2020

Nota: La página que ha solicitado no está en su idioma predeterminado. Usted está usando nuestra plataforma en otro idioma ahora.

This statistic shows the leading announced life sciences deals worldwide during 2020 by total value. During that year, U.S.-based Bristol-Myers Squibb announced and completed the takeover of MyoKardia, a deal worth 13.1 billion U.S. dollars.

Leading life sciences deals based on value worldwide in 2020* (in billion U.S. dollars)

Bidder (Target)	Value in billion U.S. dollars.
AstraZeneca (Alexion)**	39
Gilead Sciences (Immunomedics)	21
Siemens Healthineers (Vaian Medical Systems)**	16.4
Bristol-Myers Squibb (MyoKardia)	13.1
Illumina (Grail)**	8
Johnson & Johnson (Momenta)	6.5
Gilead Sciences (Forty Seven)	4.9
Bayer (Asklepios BioPharmaceutical)**	4
Sanofi (Principia Biopharma)	3.7

Loading statistic...

Download

Source

Show detailed source information?

Already a member?

Sources

Use Ask Statista Research Service

Release date

January 2021

More information

Region

Worldwide

Survey time period

2020

Supplementary notes

* Deals can also include M&As of parts/segments/divisions of companies.
Life sciences include: medicinal chemicals and botanical products; pharmaceutical preparations; in-vitro and in-vivo diagnostics; biotechnology, biological products, except diagnostic substances; pharmaceutical wholesale; medical devices and diagnostics; plant sciences.
** Pending as of publication date.

Open this statistic in...

Spanish

Citation formats